Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 44 Neoplasm Metastasis 19 Liver Neoplasms 18 Colorectal Neoplasms 15 Cholangiocarcinoma 11 Pancreatic Neoplasms 9 Lung Neoplasms 9 Colonic Neoplasms 9 Breast Neoplasms 8 Carcinoma, Renal Cell 7 Carcinoma, Non-Small-Cell Lung 7 Barrett Esophagus 7 Thyroid Nodule 6 Recurrence 6 Rectal Neoplasms 6 Thyroid Neoplasms 5 Pain 4 Neoplasms 4 Kidney Neoplasms 4 Esophageal Neoplasms 4 Thyroid Cancer, Papillary 3 Prostatic Neoplasms 3 Leiomyoma 3 Biliary Tract Neoplasms 3 Bile Duct Neoplasms 3 Agnosia 3 Thyroid Diseases 2 Hyperaldosteronism 2 Hepatitis B 2 Gallbladder Neoplasms 2

Interventions

Pemetrexed 14 Carboplatin 13 osimertinib 11 Drug Therapy 9 aflutinib 8 Gefitinib 8 Radiotherapy 6 Docetaxel 6 Cisplatin 6 pembrolizumab 5 anlotinib 5 Radiosurgery 5 Paclitaxel 5 icotinib 4 Vinorelbine 4 Gemcitabine 4 Erlotinib Hydrochloride 4 tislelizumab 3 camrelizumab 3 apatinib 3 HM781-36B 3 toripalimab 2 spartalizumab 2 rezivertinib 2 dacomitinib 2 Tyrosine Kinase Inhibitors 2 Thalidomide 2 Surgical Procedures, Operative 2 S 1 (combination) 2 Platinum 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

NSCLC × Radiofrequency Ablation × Clear all

NCT01105182 2010-04-16

FACPT

The First Affiliated Hospital of Guangzhou Medical University

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡